Latest News & Updates

Latest Articles
Active Surveillance a Valued Approach for Early Prostate Cancer
Before undergoing surgery, radiation therapy, or a systemic treatment, Clayton S. Lau, MD, advises that the active surveillance approach for some patients with early prostate cancer is likely a more effective approach—but they should be better educated on it.
PUBLISHED: October 27, 2016
First-Line Pembrolizumab Just the Beginning for Novel Approaches in Bladder Cancer
First-line pembrolizumab demonstrated significant antitumor activity in cisplatin-ineligible patients with metastatic urothelial cancer.
PUBLISHED: October 27, 2016
Novel Agents, Combinations Advance Second-Line RCC Care
The treatment paradigm of advanced renal cell carcinoma (RCC) has been rapidly changing. First, the FDA approved the combination of lenvatinib and everolimus in May 2016 as a treatment for patients with advanced RCC following prior antiangiogenic therapy.
PUBLISHED: October 27, 2016
Frontline CLL Paradigm Rapidly Evolving to Include Novel Therapies
As more agents are approved in the treatment paradigm of chronic lymphocytic leukemia, researchers are exploring frontline options—in addition to ibrutinib and the regimen of fludarabine, cyclophosphamide, and rituximab—in ongoing trials.
PUBLISHED: October 27, 2016
A Step-by-Step Guide to Value-Based Care
The evolving healthcare landscape creates many challenges for community-based oncology practices. As the market shifts from fee-for-service to value-based care, practices are tasked with improving quality while reducing costs.
PUBLISHED: October 27, 2016
Latest Peer Exchange Discussions
MDS: The Current Understanding in Molecular Testing and Biomarkers
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome. View Now
ALK-Positive Lung Cancer
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Advances in Targeted Therapy: The Emerging Role of PARP Inhibitors in the Treatment of CancersOct 30, 20162.0
Cancer Summaries and Commentaries™: Update from Vienna: Advances in the Treatment of Gastrointestinal CancersOct 30, 20161.0
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast CancerNov 16, 20161.0
Evolving Management Strategies for Triple-Negative Breast CancerNov 23, 20161.0
Publication Bottom Border
Border Publication